Physician profile
Ankit Anand
NPI 1225383359
$16,097.73
in general payments reported to CMS, 2019-2025
43 companies · $280 in 2025
The $280 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,433 · 2020: $461 · 2021: $28.46 · 2022: $5,219 · 2023: $1,463 · 2024: $214 · 2025: $280.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $987 · Food and Beverage: $970.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $987.44 |
| Food and Beverage | $969.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $6,901.98 | 2019-2020 | |
| Exelixis INC. | $4,204.06 | 2019-2025 | Cabometyx |
| Gilead Sciences, INC. | $1,339.38 | 2019-2024 | Trodelvy |
| Macrogenics, INC. | $1,083.00 | 2022 | |
| Novartis Pharmaceuticals Corporation | $316.38 | 2019-2025 | |
| Genentech USA, INC. | $177.81 | 2019-2023 | Venclexta, Phesgo |
| Merck Sharp & Dohme LLC | $176.14 | 2019-2023 | Keytruda |
| E.R. Squibb & Sons, L.L.C. | $160.74 | 2019-2024 | Augtyro, Opdualag |
| Janssen Biotech, INC. | $151.85 | 2019-2023 | Erleada |
| Pfizer INC. | $139.80 | 2019-2025 | |
| Amgen INC. | $137.91 | 2019-2023 | Lumakras |
| Celgene Corporation | $121.16 | 2019-2023 | Reblozyl |
| Astrazeneca Pharmaceuticals LP | $114.17 | 2019-2020 | |
| Astellas Pharma US INC | $113.91 | 2019-2025 | Xtandi |
| Takeda Pharmaceuticals U.S.A., INC. | $84.58 | 2019-2025 | Fruzaqla |
Show all 42 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ankit Anand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.